Comment on: “Clinical Features, Management, and Prognosis of an International Series of 161 Patients With Limited-Stage Diffuse Large B-Cell Lymphoma of the Bone (the IELSG-14 Study)”
作者： Richard Hoppe , Tim Illidge , Lena Specht , Ivan Vogelius , Joachim Yahalom
DOI: 10.1634/THEONCOLOGIST.2014-0200
关键词:
摘要: The conclusion of Ventre et al. is that patients with primary diffuse large B-cell lymphoma (DLBCL) bone should be treated anthracycline-based chemotherapy (the standard for all cases DLBCL) or without radiotherapy. study suffers from several weaknesses make the doubtful.
alphamedpress.org参考文章(2)
Gerhard Held, Samira Zeynalova, Niels Murawski, Marita Ziepert, Barbara Kempf, Andreas Viardot, Martin Dreyling, Michael Hallek, Mathias Witzens-Harig, Jochen Fleckenstein, Christian Rübe, Carsten Zwick, Bertram Glass, Norbert Schmitz, Michael Pfreundschuh, Impact of Rituximab and Radiotherapy on Outcome of Patients With Aggressive B-Cell Lymphoma and Skeletal Involvement Journal of Clinical Oncology. ,vol. 31, pp. 4115- 4122 ,(2013) , 10.1200/JCO.2012.48.0467
Marta Bruno Ventre, Andrés J.M. Ferreri, Mary Gospodarowicz, Silvia Govi, Carlo Messina, David Porter, John Radford, Dae Seog Heo, Yeon Park, Giovanni Martinelli, Emma Taylor, Helen Lucraft, Angela Hong, Lydia Scarfò, Emanuele Zucca, David Christie, , Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large b-cell lymphoma of the bone (the IELSG-14 study). Oncologist. ,vol. 19, pp. 291- 298 ,(2014) , 10.1634/THEONCOLOGIST.2013-0249